Recent Updates
Recently added Catalysts

sulfonylurea

Phase 3

Diabetes | Small molecule | Metabolic |Novo Nordisk A/S|Last Updated: Mar 8, 2017

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment264

FDA Designations

No designations recorded

Clinical trial landscape

sulfonylurea · 1 trial · 2 indications

Phase 3 1
NCT00395746Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 DiabetesDiabetes
COMPLETED264 Analytics
PHASE3COMPLETED
Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes
Diabetes
NCT00395746264
Unlock trial analytics

Study Endpoints

Primary Endpoints

Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment
after 24 weeks of treatment

Secondary Endpoints

Glycosylated Haemoglobin A1c (HbA1c) After 52 Weeks of Treatment
after 52 weeks of treatment
Fasting Plasma Glucose After 24 Weeks of Treatment
after 24 weeks of treatment
Fasting Plasma Glucose After 52 Weeks of Treatment
after 52 weeks of treatment
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
0.6 mg + SUEXPERIMENTALLiraglutide 0.6 mg + sulphonylurea
0.9 mg + SUEXPERIMENTALLiraglutide 0.9 mg + sulphonylurea
SU Mono - 1PLACEBO_COMPARATORLiraglutide placebo 0.6 mg + sulphonylurea
SU Mono - 2PLACEBO_COMPARATORLiraglutide placebo 0.9 mg + sulphonylurea

Interventions

NameTypeDescription
sulfonylureaDRUGSU agent
liraglutideDRUGLiraglutide 0.6 mg/day or placebo. Injected s.c. (under the skin) once daily.
Unlock Study Design Details

Eligibility Criteria

Age Range20 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Type 2 diabetes * Diet/exercise therapy with sulfonylurea (SU) for at least eight weeks * HbA1c greater than or equal to 7.0% and less than 10.0% * BMI less than 35 kg/m2 Exclusion Criteria: * Treatment with insulin within the last 12 weeks * Treatment with any drug that cou...

Countries:Japan
Unlock Eligibility Criteria

Competitive Landscape -Diabetes Complications 6 trials (matched to "Diabetes")

CompanyTickerTrialsLead PhaseDrugs
FibroBiologics, Inc.FBLG1PHASE1Undisclosed
MiMedx Group, Inc.MDXG2N/AUndisclosed
Integra LifeSciences Holdings CorporationIART1N/AUndisclosed
Organogenesis Holdings, Inc. Class AORGO1N/AUndisclosed
Healthcare Services Group, Inc.HCSG1N/AUndisclosed
Unlock Competitive Intelligence

Frequently asked questions about sulfonylurea

What is sulfonylurea used for?

Sulfonylurea is an investigational small molecule being studied for the treatment of type 2 diabetes. It is being evaluated in combination with liraglutide to improve blood glucose control in patients with type 2 diabetes. The drug is currently in Phase 3 clinical development.

Who makes sulfonylurea?

Sulfonylurea is being developed by Novo Nordisk A/S, a pharmaceutical company traded on the NYSE under the ticker symbol NVO. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with type 2 diabetes.

What phase is sulfonylurea in?

Sulfonylurea is in Phase 3 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. A Phase 3 clinical trial has been completed to evaluate its effects on blood glucose control in patients with type 2 diabetes.

What clinical trials is sulfonylurea in?

Sulfonylurea has been studied in one completed Phase 3 clinical trial with the identifier NCT00395746. The trial, titled 'Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes,' enrolled 264 participants in Japan and was placebo-controlled and double-blind.

Is sulfonylurea the same as liraglutide?

No, sulfonylurea is not the same as liraglutide. Sulfonylurea is an investigational small molecule being studied in combination with liraglutide for the treatment of type 2 diabetes. The two drugs have different mechanisms of action and are being evaluated together in clinical trials.